Brokerages expect Amarin Co. plc (NASDAQ:AMRN) to announce sales of $146.73 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Amarin’s earnings, with the lowest sales estimate coming in at $125.25 million and the highest estimate coming in at $156.00 million. Amarin posted sales of $100.79 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 45.6%. The firm is scheduled to announce its next earnings report on Wednesday, July 29th.
According to Zacks, analysts expect that Amarin will report full year sales of $664.29 million for the current financial year, with estimates ranging from $605.74 million to $700.30 million. For the next fiscal year, analysts anticipate that the business will post sales of $824.21 million, with estimates ranging from $270.80 million to $1.10 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Amarin.
Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Amarin had a negative net margin of 3.67% and a negative return on equity of 4.05%. The firm had revenue of $155.00 million for the quarter, compared to analyst estimates of $150.06 million. During the same period in the previous year, the company earned ($0.05) earnings per share. The business’s quarterly revenue was up 111.5% compared to the same quarter last year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. NWK Group Inc. purchased a new stake in Amarin during the 4th quarter valued at about $47,000. Partner Investment Management L.P. acquired a new stake in shares of Amarin in the 4th quarter valued at $81,000. Sunbelt Securities Inc. acquired a new stake in shares of Amarin in the 4th quarter valued at $24,924,000. Exane Derivatives acquired a new stake in shares of Amarin in the 1st quarter valued at $29,000. Finally, Amundi Pioneer Asset Management Inc. raised its holdings in shares of Amarin by 13.7% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 7,394 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 893 shares in the last quarter. 44.36% of the stock is owned by institutional investors.
NASDAQ:AMRN traded down $0.22 during mid-day trading on Friday, hitting $6.70. The company’s stock had a trading volume of 5,024,867 shares, compared to its average volume of 6,895,756. The business’s fifty day moving average is $7.12 and its two-hundred day moving average is $13.23. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -111.67 and a beta of 2.71. Amarin has a 1 year low of $3.95 and a 1 year high of $26.12.
Amarin Company Profile
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.